Zhejiang East-Asia Pharmaceutical (605177.SH): Sitagliptin Metformin Sustained-Release Tablets Obtain Drug Registration Certificate.
East Asia Pharma (605177.SH) announced that the company has received the "Drug Registration Certificate" issued by the National Medical Products Administration for acarbose and metformin sustained-release tablets (I) and (III). Acarbose and metformin sustained-release tablets are used in combination with diet and exercise therapy to improve blood sugar control in adult patients with type 2 diabetes who are already receiving acarbose and metformin treatment.
Zhejiang East-Asia Pharmaceutical (605177.SH) announced that the company has received the "Drug Registration Certificate" for saxagliptin and metformin sustained-release tablets (I) and (III) approved and issued by the State Drug Administration. Saxagliptin and metformin sustained-release tablets, in combination with diet and exercise therapy, are suitable for type 2 diabetes adult patients who are already receiving saxagliptin and metformin treatment to improve blood sugar control in such patients.
Related Articles
MIN XIN HOLD (00222) announces profit growth, with estimated annual net profit attributable to shareholders of approximately HK$1.1 billion to HK$1.3 billion, a year-on-year increase of about 25% to 48%.
CHINA EB LTD (00165) completes the issuance of RMB 2 billion medium-term notes.
Ming Liang Holdings (08152) released a profit announcement, expecting a post-tax profit of approximately HKD 8 to 9 million for the year 2025, turning from a loss to a profit year-on-year.
MIN XIN HOLD (00222) announces profit growth, with estimated annual net profit attributable to shareholders of approximately HK$1.1 billion to HK$1.3 billion, a year-on-year increase of about 25% to 48%.
CHINA EB LTD (00165) completes the issuance of RMB 2 billion medium-term notes.
Ming Liang Holdings (08152) released a profit announcement, expecting a post-tax profit of approximately HKD 8 to 9 million for the year 2025, turning from a loss to a profit year-on-year.
